European Patent Office award decision

Theracryf PLC

27 November 2024

 

RNS REACH

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

European Patent Office decision to award patent for Ox-1 antagonist

Alderley Park, UK - 27 November 2024: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry has received the decision from the European Patent Office to award a Composition of Matter patent for its Orexin 1 (Ox-1) receptor antagonist in Europe, with a formal grant to be made on 18 December 2024.

TheraCryf's highly selective Ox-1 receptor antagonist was acquired as part of its acquisition of Chronos Therapeutics Ltd in April 2024.  An imbalance in Orexin production and stimulation of the Orexin 1 receptor in the brain has been linked to anxiety, addiction and other  mental health conditions. An Orexin 1 receptor antagonist inhibits the effect of Orexin on this receptor, potentially providing effective treatments for these disorders. TheraCryf's Ox-1 is the most selective Orexin 1  receptor antagonist thus far discovered and is currently at late pre-clinical stage.

This patent adds to TheraCryf's extensive international IP portfolio covering its oncology and neuropsychiatry products.  

Dr Huw Jones, TheraCryf's CEO, commented:

"Composition of Matter patents such as this are the strongest form of intellectual property available. This decision will give extensive protection for our candidate Ox-1 receptor antagonist and associated novel molecular structures in the broad group of territories covered by the European Patent Office, complementing the patents in this family already awarded  in the USA and Asia."

-Ends-

Enquiries

TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, CBO	[phone] [e-mail]
Cavendish Capital Markets (NOMAD and Broker) Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance) Nigel Birks / Harriet Ward (ECM)	[phone]
Vigo Consulting Rozi Morris	[phone] [e-mail]

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. As well as a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders.  The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF. 

For further information, please visit: www.theracryf.com 

 

END